Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Procept BioRobotics Corp

NASDAQ: PRCT · Industrial Applications and Services · 6 alerts · CIK 1588978

Share price
$23.54Close, Nov 16
Market cap
$1.35B
Shares outstanding
57.54MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Procept BioRobotics Corp filings on SEC EDGAR ↗

6:14 PM ET Form 4
Insider Selling

Procept BioRobotics Chief Strat/Marketing Officer Pooja Sharma Sells $92.9K of Stock

Pooja Sharma, Chief Strat/Marketing Officer, sold 4,710 shares of Procept BioRobotics Corp at $19.71 a share, worth $92.9K in total on Nov 6, 2026. Shares held after the trade: 106,471 (-4.2%).

Value
$92.9K
Shares
4,710
Price
$19.71
Role
Chief Strat/Marketing Officer
Holding change
-4.2%
Trade date
Nov 6, 2026
4:51 PM ET 10-Q
Financial Results ▶ Call

Procept BioRobotics Q3 2026 Results: Net Loss of $26.5M, Loss Widens

For the quarter ended September 30, 2026, PROCEPT BioRobotics reported revenue of $98.3 million, a 18% increase compared to the same period in 2025. Despite the revenue growth, the company reported a net loss of $26.5 million for the quarter, driven by increased selling, general, and administrative expenses.

Key figure
Net loss $26.5M
4:19 PM ET 8-K
Financial Results

Procept BioRobotics Financial Results

PROCEPT BioRobotics reported Q3 2026 total revenue of $98.3 million, an increase of 18% year-over-year, driven by strong U.S. procedure growth and the rollout of its HYDROS systems. The company reported a net loss of $26.5 million for the quarter while reaffirming its full-year 2026 revenue guidance of $390 million to $410 million.

Term
Q3 2026

“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan. Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”

Larry Wood, Chief Executive Officer

“This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”

Larry Wood, Chief Executive Officer
4:47 PM ET 8-K
Leadership Change

Procept BioRobotics Leadership Change

PROCEPT BioRobotics Corporation has expanded its board of directors from nine to ten members and appointed Dr. Michael Mack as a new independent Class II director, effective October 2, 2026. Dr. Mack, a highly published cardiac surgeon and healthcare executive, will serve until the 2029 annual meeting of stockholders. He will receive compensation consistent with the company's existing non-employee director program.

4:45 PM ET 8-K
Loan & Debt

Procept BioRobotics Debt Financing Update with Canadian Imperial Bank of Commerce

PROCEPT BioRobotics Corporation entered into a third amendment to its existing Loan and Security Agreement with CIBC. The amendment extends the maturity date of the term loan by 12 months, from October 1, 2027, to October 1, 2028.

Counterparty
Canadian Imperial Bank of Commerce
Term
through Oct 2028

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.